Lynk Pharmaceuticals Reports Positive Long-Term Phase III Zemprocitinib Results
Lynk Pharmaceuticals reported positive long-term Phase III results for zemprocitinib in bDMARD-inadequate responders with moderate-to-severe rheumatoid arthritis.
Lynk Pharmaceuticals reported positive long-term Phase III results for zemprocitinib in bDMARD-inadequate responders with moderate-to-severe rheumatoid arthritis.